Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › eltrombopag

eltrombopag

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of eltrombopag

30 trials tracked of eltrombopag: 7 in phase 3 or 4 and 1 with published results. The most-cited published study has 11 citations.

30Trials tracked
7Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 7 Phase 2 22 Phase 1 1
  1. Phase 3 Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children Completed · 11 cited
  2. Phase 3 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Completed
  3. Phase 3 Eltrombopag Phase III Study In Chinese Chronic ITP Patients Completed
  4. Phase 3 RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag Completed
  5. Phase 3 Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 Completed
  6. Phase 3 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease Completed
Show 24 more trials
  1. Phase 3 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease Completed
  2. Phase 2 A Safety and Efficacy Study of Eltrombopag in Subjects With AML Completed
  3. Phase 2 Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease Completed
  4. Phase 2 Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag Completed
  5. Phase 2 Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) Completed
  6. Phase 2 Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia Completed
  7. Phase 2 Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects Completed
  8. Phase 2 Extended Dosing With Eltrombopag for Severe Aplastic Anemia Completed
  9. Phase 2 Safety and Efficacy of Eltrombopag at Escalated Doses Completed
  10. Phase 2 Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS) Completed
  11. Phase 2 A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed
  12. Phase 2 Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) Completed
  13. Phase 2 Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT) Completed
  14. Phase 2 A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP Completed
  15. Phase 2 Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia Completed
  16. Phase 2 A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients Completed
  17. Phase 2 A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) Completed
  18. Phase 2 Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects. Completed
  19. Phase 2 Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) Completed
  20. Phase 2 Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia Completed
  21. Phase 2 A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP Completed
  22. Phase 2 Eltrombopag for Moderate Aplastic Anemia Completed
  23. Phase 2 Eltrombopag for Post Transplant Thrombocytopenia Completed
  24. Phase 1 Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation Completed

Showing the 30 most-cited and recently-updated of 30 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ianalumab plus eltrombopag extends time to treatment failure in primary ITP adults
Hematology RCT
Ianalumab plus eltrombopag extends time to treatment failure in primary ITP adults Study tests ianalumab plus eltrombopag for adults with immune thrombocytopenia
This phase 3 randomized, double-blind trial in 152 adults with primary ITP and insufficient response to glucocorticoids found that ianalumab…
Adding ianalumab to standard therapy helped more adults with immune thrombocytopenia stay stable and avoid treatment failure compared to pla…
Jun 4, 2026
Eltrombopag addition alters clonal hematopoiesis dynamics in untreated severe aplastic anemia patients over 24 months
Drug Pipeline RCT
Eltrombopag addition alters clonal hematopoiesis dynamics in untreated severe aplastic anemia patients over 24 months Adding Eltrombopag helps severe anemia patients recover blood counts significantly faster
This Phase 3 randomized trial reviewed patient samples from 170 untreated patients with severe or very severe aplastic anemia receiving eltr…
Adding Eltrombopag helps severe anemia patients recover blood counts faster without increasing cancer risks but genetic changes rise over ti…
NEJM Evid Apr 28, 2026
Eltrombopag plus immunosuppression for severe aplastic anemia shows clonal evolution patterns
Pediatrics Phase II
Eltrombopag plus immunosuppression for severe aplastic anemia shows clonal evolution patterns Treatment for severe anemia reveals two paths to cancer risk
This phase 2 observational study followed 204 patients with severe aplastic anemia treated with immunosuppression plus eltrombopag for a med…
New research tracks cancer risks in severe anemia patients treated with standard therapy over five years
NEJM Evid Apr 28, 2026
Eltrombopag monotherapy assessed in moderate aplastic anemia and unilineage bone marrow failure disorders
Hematology Phase II
Eltrombopag monotherapy assessed in moderate aplastic anemia and unilineage bone marrow failure disorders Oral Drug May Reduce Need for Frequent Blood Transfusions
This Phase 2 trial evaluated eltrombopag by mouth once a day in 34 people at least 2 years of age with moderate aplastic anemia or unilineag…
A new oral medication offers hope for patients who rely on regular blood transfusions.
CT.gov Apr 24, 2026